Appendix

Ozone Therapy #7971 - Microbiological aspects of ozone

Supplementary Table 1. Antimicrobial susceptibility of *E. coli* before and post-exposure to O_2O_3.

ANTIBIOTIC	*E. coli* from urine						*E. coli* from urine (+O_2O_3)					
	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR
Amikacin	≤4	S	≤4	S	≤4	S	≤4	S	≤4	S	≤4	S
Amoxicillin-clavulanate	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R
Ampicillin	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Aztreonam	4	I	4	I	4	I	4	I	4	I	4	I
Cefepime	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Ceftazidime	4	I	4	I	4	I	4	I	4	I	4	I
Ceftriaxone	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	1	S	≤0.5	S
Cefuroxime	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Ciprofloxacin	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S
Colistin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Ertapenem	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S
Fosfomicin c/G6P	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S
Gentamicin	2	S	1	S	2	S	≤1	S	2	S	2	S
Imipenem	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S
Levofloxacin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Meropenem	≤0.125	S	≤0.125	S	≤0.125	S	≤0.125	S	≤0.125	S	≤0.125	S
Norfloxacin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Piperacillin	16	I	32	R	16	I	16	I	32	R	32	R
Piperacillin-tazobactam	16/4	I	16/4	I	16/4	I	16/4	I	16/4	I	16/4	I
Ticarcillin-clavulanate	64/2	R	64/2	R	64/2	R	32/2	R	64/2	R	64/2	R
Tigeciclin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Tobramicin	≤1	S	2	S	2	S	≤1	S	≤1	S	≤1	S
Trimethoprim-sulfametoxazolo	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S

Non commercial use only

Supplementary Table 2. Antimicrobial susceptibility of *P. mirabilis* before and post-exposure to O_2O_3.

ANTIBIOTIC	*P. mirabilis* from tracheal aspirate						*P. mirabilis* from tracheal aspirate (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	8	S	8	S	8	S	8	S	8	S	8	S
Amoxicillin-clavulanate	≤2/2	S	≤2/2	S	≤2/2	S	≤2/2	S	≤2/2	S	≤2/2	S
Ampicillin	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Aztreonam	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Cefepime	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Ceftazidime	1	S	1	S	1	S	1	S	1	S	1	S
Ceftriaxone	1	S	1	S	1	S	1	S	1	S	1	S
Cefuroxime	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Ciprofloxacin	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Colistin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Ertapenem	**≥0.25**	**S**	**≥0.25**	**S**	**>1**	**R**	**≥0.25**	**S**	**≥0.25**	**S**	**>1**	**R**
Fosfomicin c/G6P	**128**	R	**128**	R	**64**	R	**64**	R	**128**	R	**64**	R
Gentamicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Levofloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Meropenem	≥0.5	S	≥0.5	S	≥0.5	S	≥0.5	S	≥0.5	S	≥0.5	S
Norfloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Piperacillin	>64	R	>64	R	>64	R	>64	R	>64	R	>64	R
Piperacillin-tazobactam	≤4/4	S	≤4/4	S	≤4/4	S	≤4/4	S	≤4/4	S	≤4/4	S
Ticarcillin-clavulanate	≤4/2	S	≤4/2	S	≤4/2	S	≤4/2	S	≤4/2	S	≤4/2	S
Tobramicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Trimethoprim-sulfametoxazolo	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S

Non commercial use only

Supplementary Table 3. Antimicrobial susceptibility of *K. pneumoniae*$_{(1)}$ before and post-exposure to O_2O_3.

ANTIBIOTIC	*K. pneumoniae* from urine						*K. pneumoniae* from urine (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Amoxicillin-clavulanate	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R
Ampicillin	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Aztreonam	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Cefepime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftazidime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftriaxone	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Cefuroxime	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Ciprofloxacin	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Colistin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Ertapenem	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Fosfomicin c/G6P	**32**	**S**	**64**	**R**	**64**	**R**	**32**	**S**	**64**	**R**	**64**	**R**
Gentamicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Levofloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Mecillinam	-	R	-	R	-	R	-	R	-	R	-	R
Meropenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Norfloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Piperacillin	>64	R	>64	R	>64	R	>64	R	>64	R	>64	R
Piperacillin-tazobactam	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R
Ticarcillin-clavulanate	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R
Tigeciclin	2	I	2	I	2	I	2	I	2	I	2	I
Tobramicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Trimethoprim-sulfametoxazolo	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S

Non commercial use only

Supplementary Table 4. Antimicrobial susceptibility of *K. pneumoniae*$_{(2)}$ before and post-exposure to O_2O_3.

ANTIBIOTIC	*K. pneumoniae* from tracheal aspirate						*K. pneumoniae* from tracheal aspirate (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Amoxicillin-clavulanate	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R
Ampicillin	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Aztreonam	>16	R	16	R	16	R	>16	R	16	R	16	R
Cefepime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftazidime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftriaxone	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Cefuroxime	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Ciprofloxacin	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Colistin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Ertapenem	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Fosfomicin c/G6P	32	S	32	S	32	S	32	S	32	S	32	S
Gentamicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Levofloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Mecillinam	-	R	-	R	-	R	-	R	-	R	-	R
Meropenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Norfloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Piperacillin	>64	R	>64	R	>64	R	>64	R	>64	R	>64	R
Piperacillin-tazobactam	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R
Ticarcillin-clavulanate	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R
Tigeciclin	**2**	**I**	**2**	**I**	**1**	**S**	2	I	2	I	2	I
Tobramicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Trimethoprim-sulfametoxazolo	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S

Non commercial use only

Supplementary Table 5. Antimicrobial susceptibility of *K. pneumoniae*(3) before and post-exposure to O_2O_3.

ANTIBIOTIC	*K. pneumoniae* from wound swab						*K. pneumoniae* from wound swab (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Amoxicillin-clavulanate	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R	>32/2	R
Ampicillin	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Aztreonam	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Cefepime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftazidime	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftriaxone	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Cefuroxime	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Ciprofloxacin	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Colistin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Ertapenem	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Fosfomicin c/G6P	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	32	S
Gentamicin	**2**	**S**	**>4**	**R**	**>4**	**R**	**2**	**S**	**>4**	**R**	**>4**	**R**
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Levofloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Mecillinam	-	R	-	R	-	R	-	R	-	R	-	R
Meropenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Norfloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Piperacillin	>64	R	>64	R	>64	R	>64	R	>64	R	>64	R
Piperacillin-tazobactam	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R	>64/4	R
Ticarcillin-clavulanate	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R	>64/2	R
Tigeciclin	2	I	2	I	2	I	2	I	2	I	2	I
Tobramicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Trimethoprim-sulfametoxazolo	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S	≤1/19	S

Non commercial use only

Supplementary Table 6. Antimicrobial susceptibility of *P. aeruginosa* before and post-exposure to O_2O_3.

ANTIBIOTIC	*P. aeruginosa* from tracheal aspirate						*P. aeruginosa* from tracheal aspirate (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	≤4	S	≤4	S	≤4	S	≤4	S	≤4	S	≤4	S
Aztreonam	16	I	16	I	16	I	16	I	16	I	16	I
Cefepime	8	S	8	S	8	S	8	S	8	S	8	S
Ceftazidime	8	S	8	S	8	S	8	S	8	S	8	S
Ciprofloxacin	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	≤0.25	S
Colistin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Gentamicin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Imipenem	2	S	2	S	2	S	2	S	2	S	2	S
Levofloxacin	**2**	**R**	**2**	**R**	**2**	**R**	**2**	**R**	**2**	**R**	**1**	**S**
Meropenem	0.5	S	0.5	S	0.5	S	1	S	1	S	0.5	S
Piperacillin	32	R	32	R	32	R	32	R	32	R	32	R
Piperacillin-tazobactam	**32/4**	**R**	**32/4**	**R**	**32/4**	**R**	**16/4**	**S**	**16/4**	**S**	**32/4**	**R**
Ticarcillin-clavulanate	**64/2**	**R**	**64/2**	**R**	**16/2**	**S**	**64/2**	**R**	**64/2**	**R**	**64/2**	**R**
Tobramicin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S

Non commercial use only

Supplementary Table 7. Antimicrobial susceptibility of *A. baumannii* before and post-exposure to O_2O_3.

ANTIBIOTIC	*A. baumannii* from tracheal aspirate						*A. baumannii* from tracheal aspirate (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Amikacin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ciprofloxacin	>1	R	>1	R	>1	R	>1	R	>1	R	>1	R
Colistin	≤ 1	S	≤ 1	S	≤ 1	S	≤ 1	S	≤ 1	S	≤ 1	S
Gentamicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Levofloxacin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R
Meropenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Tobramicin	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Trimethoprim-sulfametoxazolo	>4/76	R	>4/76	R	>4/76	R	>4/76	R	>4/76	R	>4/76	R

Non commercial use only

Supplementary Table 8. Antimicrobial susceptibility of *S. aureus* before and post-exposure to O_2O_3.

ANTIBIOTIC	*S. aureus* from urine						*S. aureus* from urine (+O_2O_3)					
	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR
Fusidic acid	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Ampicillin	1	S	1	S	1	S	ND	ND	ND	ND	ND	ND
Ceftriaxone	-	R	-	R	-	R	ND	ND	ND	ND	ND	ND
Ciprofloxacin	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Clindamicin	-	R	-	R	-	R	ND	ND	ND	ND	ND	ND
Cloramfenicolo	8	S	8	S	4	S	ND	ND	ND	ND	ND	ND
Daptomicin	0.5	S	0.5	S	0.5	S	ND	ND	ND	ND	ND	ND
Eritromicin	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Fosfomicina c/G6P	64	R	64	R	64	R	ND	ND	ND	ND	ND	ND
Gentamicin	≤1	S	≤1	S	≤1	S	ND	ND	ND	ND	ND	ND
Levofloxacin	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Linezolid	2	S	2	S	2	S	ND	ND	ND	ND	ND	ND
Moxifloxacin	>2	R	>2	R	>2	R	ND	ND	ND	ND	ND	ND
Mupirocina	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Mupirocina alto livello	≤256	S	≤256	S	≤256	S	ND	ND	ND	ND	ND	ND
Oxacillin	>2	R	>2	R	>2	R	ND	ND	ND	ND	ND	ND
Penicillina G	>0.25	R	>0.25	R	>0.25	R	ND	ND	ND	ND	ND	ND
Quinupristin-dalfopristin	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Rifampicin	≤0.25	X	≤0.25	X	≤0.25	X	ND	ND	ND	ND	ND	ND
Teicoplanina	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Tetraciclina	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Tigeciclina	0.25	S	0.25	S	0.25	S	ND	ND	ND	ND	ND	ND
Tobramicina	≤1	S	≤1	S	≤1	S	ND	ND	ND	ND	ND	ND
Trimethoprim-sulfametoxazolo	≤0.5/9.5	S	≤0.5/9.5	S	≤0.5/9.5	S	ND	ND	ND	ND	ND	ND
Vancomicin	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND

Non commercial use only

Supplementary Table 9. Antimicrobial susceptibility of *S. epidermidis* before and post-exposure to O_2O_3.

ANTIBIOTIC	*S. epidermidis* from wound swab						*S. epidermidis* from wound swab (+O_2O_3)					
	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR
Fusidic acid	4	R	8	R	8	R	ND	ND	ND	ND	ND	ND
Ampicillin	-	R	-	R	-	R	ND	ND	ND	ND	ND	ND
Ceftriaxone	-	R	-	R	-	R	ND	ND	ND	ND	ND	ND
Ciprofloxacin	2	R	4	R	4	R	ND	ND	ND	ND	ND	ND
Clindamicin	-	R	-	R	-	R	ND	ND	ND	ND	ND	ND
Cloramfenicolo	4	S	4	S	8	S	ND	ND	ND	ND	ND	ND
Daptomicin	0.5	S	0.5	S	0.5	S	ND	ND	ND	ND	ND	ND
Eritromicin	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Fosfomicina c/G6P	≤16	S	≤16	S	≤16	S	ND	ND	ND	ND	ND	ND
Gentamicin	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Levofloxacin	4	R	4	R	4	R	ND	ND	ND	ND	ND	ND
Linezolid	2	S	2	S	2	S	ND	ND	ND	ND	ND	ND
Moxifloxacin	0.5	R	0.5	R	0.5	R	ND	ND	ND	ND	ND	ND
Oxacillin	>2	R	>2	R	>2	R	ND	ND	ND	ND	ND	ND
Quinupristin-dalfopristin	≤0.5	S	≤0.5	S	≤0.5	S	ND	ND	ND	ND	ND	ND
Rifampicin	≤0.25	X	≤0.25	X	≤0.25	X	ND	ND	ND	ND	ND	ND
Teicoplanina	≤2	S	≤2	S	≤2	S	ND	ND	ND	ND	ND	ND
Tetraciclina	>2	R	>2	R	>2	R	ND	ND	ND	ND	ND	ND
Tigeciclina	≤0.125	S	≤0.125	S	≤0.125	S	ND	ND	ND	ND	ND	ND
Tobramicina	>4	R	>4	R	>4	R	ND	ND	ND	ND	ND	ND
Trimethoprim-sulfametoxazolo	≤0.5/9.5	S	≤0.5/9.5	S	≤0.5/9.5	S	ND	ND	ND	ND	ND	ND
Vancomicin	1	S	1	S	1	S	ND	ND	ND	ND	ND	ND

Non commercial use only

Supplementary Table 10. Antimicrobial susceptibility of *E. faecium*(1) before and post-exposure to O_2O_3.

ANTIBIOTIC	*E. faecium* from wound swab						*E. faecium* from wound swab (+O_2O_3)					
	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR
Ampicillin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftriaxone	-	R	-	R	-	R	-	R	-	R	-	R
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Linezolid	2	S	2	S	2	S	2	S	2	S	2	S
Quinupristin-dalfopristin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Teicoplanina	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Trimethoprim-sulfametoxazolo	-	R	-	R	-	R	-	R	-	R	-	R
Vancomicin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S

Supplementary Table 11. Antimicrobial susceptibility of *E. faecium*(2) before and post-exposure to O_2O_3.

ANTIBIOTIC	*E. faecium* from wound swab						*E. faecium* from wound swab (+O_2O_3)					
	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR	MIC	SIR
Ampicillin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R
Ceftriaxone	-	R	-	R	-	R	-	R	-	R	-	R
Imipenem	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R
Linezolid	2	S	2	S	2	S	2	S	2	S	2	S
Quinupristin-dalfopristin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Teicoplanina	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Trimethoprim-sulfametoxazolo	-	R	-	R	-	R	-	R	-	R	-	R
Vancomicin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S

Non commercial use only

Supplementary Table 12. Antimicrobial susceptibility of *S. agalactiae* before and post-exposure to O_2O_3.

ANTIBIOTIC	*S. agalactiae* from wound swab						*S. agalactiae* from wound swab (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Ceftriaxone	-	S	-	S	-	S	-	S	-	S	-	S
Clindamicin	≥0.5	R	≥0.5	R	≥0.5	R	≥0.5	R	≥0.5	R	≥0.5	R
Cloramfenicolo	≤2	S	≤2	S	≤2	S	≤2	S	≤2	S	≤2	S
Daptomicin	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S
Eritromicin	>0.5	R	>0.5	R	>0.5	R	>0.5	R	>0.5	R	>0.5	R
Levofloxacin	**1**	**S**	**1**	**S**	**1**	**S**	**≤0.5**	**S**	**≤0.5**	**S**	**≤0.5**	**S**
Linezolid	1	S	1	S	1	S	1	S	1	S	1	S
Moxifloxacin	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S	≤0.25	S
Penicillina G	0.0625	S	0.0625	S	0.0625	S	0.0625	S	0.0625	S	0.0625	S
Teicoplanina	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S
Tetraciclina	>4	R	>4	R	>4	R	>4	R	>4	R	>4	R
Vancomycin	**1**	**S**	**1**	**S**	**1**	**S**	**1**	**S**	**≤0.5**	**S**	**≤0.5**	**S**

Supplementary Table 13. Antimicrobial susceptibility of *C. striatum* before and post-exposure to O_2O_3.

ANTIBIOTIC	*C. striatum* from wound swab						*C. striatum* from wound swab (+O_2O_3)					
	MIC	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**	**MIC**	**SIR**
Penicillin	≥32	R	≥32	R	≥32	R	≥32	R	≥32	R	≥32	R
Ciprofloxacin	≥32	R	≥32	R	≥32	R	≥32	R	≥32	R	≥32	R
Gentamicine	2	R	2	R	2	R	2	R	2	R	2	R
Vancomicin	0.25	S	0.25	S	0.25	S	0.25	S	0.25	S	0.25	S
Tetraciclina	32	R	32	R	32	R	32	R	32	R	32	R
Clindamicina	≥256	R	≥256	R	≥256	R	≥256	R	≥256	R	≥256	R
Linezolid	1	S	1	S	1	S	1	S	1	S	1	S
Rifampicina	0.016	S	0.016	S	0.016	S	0.016	S	0.016	S	0.016	S

Non commercial use only